Triastek’s T22 3D printed gastric retention drug receives FDA clearance

Chinese drug 3D printing firm Triastek has announced that its T22 3D printed gastric retention product has become the first drug of its kind to receive Investigational New Drug (IND) clearance from the US Food and Drug Administration (FDA).  T22 has been filed under section 505(B)(2) of the FDA’s Federal Food, Drug, and Cosmetic Act. […]